Asthma and COPD Drugs Market Analysis

End User (Asthma Patients, COPD Patients)

The COPD patients segment in the asthma and COPD drugs market is expected to witness around 60% growth rate through 2037. The growth of the segment can be accredited to the increasing prevalence of smoking.

Smoking is a major cause of COPD. While smoking rates have been declining in many parts of the world, there are still significant numbers of smokers, particularly in low- and middle-income countries. This is estimated to contribute to the increasing prevalence of COPD and drive demand for COPD drugs.

Distribution Channel (General Pharmacies, Online Retailers, Hospital Pharmacies)

The hospital pharmacies segment is estimated to gain the largest market share in the year 2037. Respiratory diseases such as asthma and COPD can require hospitalization, particularly in severe cases. The increasing prevalence of these conditions is likely to lead to an increase in hospitalizations, which is likely to drive demand for asthma and COPD drugs in hospital pharmacies.

According to a study of 2020, hospitalizations for asthma increased during the COVID-19 pandemic in several countries, across the globe. The study found that hospitalizations for asthma increased by 30-70% in these countries during the pandemic.

Our in-depth analysis of the global market includes the following segments: